Cen Biotech Inc's ROA from the third quarter of 2022 to the third quarter of 2021 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Cen Biotech Inc's ROA in the third quarter of 2022?
Cen Biotech Inc recorded a cumulative net loss of $-3 million during 12 months ending in the third quarter of 2022, resulting in a negative return on assets (ROA) of -46.88%.

However, within the Healthcare sector 619 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2022 quarter, so far to 4631, from total ROA ranking in the second quarter of 2022 at 4884.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2022) III. Quarter	(Jun 30 2022) II. Quarter	(Mar 31 2022) I. Quarter	(Dec 31 2021) IV. Quarter	(Sep 30 2021) III. Quarter
Y / Y Total Assets Change	-17.44 %	39.36 %	39.61 %	39.79 %	32.11 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-3	-3	-19	-19	2
Return On Assets (TTM)	-46.88 %	-49.42 %	-289.76 %	-319.54 %	42.44 %
CENB's Total Ranking	# 4631	# 4884	# 5530	# 5878	# 191
Total Assets (TTM) in million	6	7	7	7	7
Seq. Total Assets Change	-12.55 %	-1.97 %	-2.28 %	-1.45 %	47.6 %
Seq. Net Income Change	-	-	-	-	-

CENB's 5 Years Annual ROA >> Back to CENB Management Effectiveness >> Compare CENB ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 250
Sector	# 620
Overall	# 4535

Return On Assets Statistics
High	Average	Low
206.41 %	-74.3 %	-227.47 %
(Mar 31 2021)		(Dec 31 2021)

Financial Statements
Cen Biotech Inc's Assets	$ 6 million	CENB's Balance sheet
Cen Biotech Inc's Income	$ 0 million	Quarterly CENB's Income Statement
CENB's Income by Division		See CENB's Income by Division

Annual Return On Assets	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019	(Dec 31 2018) FY 2018	(Dec 31 2017) FY 2017
Y / Y Total Assets Change	39.79 %	-19.56 %	-14.9 %	-19.01 %	119.25 %
Total Assets in million	7	5	6	7	9
Y / Y Net Income Change	-95.74 %	-	-	-	-
Net Income in million	1	14	-6	-8	-14
Annual Return On Assets	8.73 %	286.37 %	-91.42 %	-103.59 %	-156.87 %

CENB's 5 Years Annual ROA >> Back to CENB Management Effectiveness >> Compare CENB ROA to its Competitors

Comment on CENB's ROA in the fiscal year ending 2021

In the fiscal year 2021 Cen Biotech Inc's ROA decreased compared to previous year to 8.73 %, due to deterioration of net income -95.74 % to $0.61 million, from $14.25 million a year ago, as CENB's assets were $6.96 million.

More Return On Assets Ratios
CENB's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CENB's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CENB's Competitors
Subscribers only: Roa for Cen Biotech Inc's Suppliers
Subscribers only: Return On Assets for CENB's Customers

You may also want to know
CENB's Roi	CENB's Inventory Turnover Ratio	CENB's Growth Rates	CENB's Dividend Comparisons
	CENB's Profitability Ratios	CENB's Asset Turnover Ratio	CENB's Dividend Growth
CENB's Roe	CENB's Valuation Ratios	CENB's Financial Strength Ratios	CENB's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2022, within Healthcare Sector

ROA

Date modified: 2026-08-30T04:42:39+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.